Cornerstone Genomics, a pioneer in advanced genomic research software, proudly announces the launch of CodeXome, a groundbreaking all-in-one platform designed to accelerate the discovery of genetic targets by providing researchers with extensive cross-species data. Tailored for genome scientists in academia, government, and private enterprise, the cloud-based CodeXome offers a unique opportunity to study gene function and evolution across species. Users can explore genes, test hypotheses, and even upload their own data for cross-referencing against Cornerstone Genomics’ proprietary database.
Founder Jill Pecon-Slattery, who initiated the project in 2019, has overseen significant company growth leading up to CodeXome’s 2024 release. She says, “I’m excited because it integrates multiple disciplines. Our platform uses genetic data that no one else has. Drawing insight from non-human primates – our extended family of monkeys, lemurs, marmosets, and others – allows scientists to reference individual genes and observe how they can evolve.”
“Most of these species are endangered,” continues Pecon-Slattery, noting a growing global interest in conservation. “CodeXome not only aids researchers in drug development and disease diagnosis, but it also raises awareness about the conservation of endangered species, linking wildlife biodiversity with human biomedicine.”
Cornerstone Genomics is a member of the Frederick Innovative Technology Center’s (FITCI) new Maryland’s EDGE at 321 in Frederick, Maryland. FITCI CEO Kathie Callahan Brady, a mentor and ardent supporter of the Cornerstone team, emphasizes CodeXome’s importance. “Typically, there is less attention for understanding the genetics of these species,” she explains. “That’s what makes CodeXome so crucial. Scientists looking for cures to rare diseases or physicians working with individual subjects can unlock a wealth of comparative information that can help them advance their vital work right now.”
Pecon-Slattery is passionate about Cornerstone Genomic’s mission because, “I want to bring attention to larger societal issues, like preservation of species around the world.” Importantly, CodeXome relies upon lab-grown cell lines, using very small initial samples, like commercial DNA tests, thereby safeguarding the lives of animals.
Early reviews praise CodeXome’s blazing speed, intuitive interface, and access to a broad primate genome spectrum. “We are honored by the support of the National Science Foundation for our transformative approach,” says Pecon-Slattery. The company received both Phase 1 and Phase 2 SBIR awards. “The NSF awards are significant milestones for us, reinforcing the value of CodeXome within the scientific community.”
Pecon-Slattery concludes, “The bottom line is, if you know what’s normal, you can better identify what’s not. CodeXome cuts through the noise to provide clear, actionable insights for researchers tackling some of the most challenging genetic diseases.”
About Cornerstone Genomics
Cornerstone Genomics is a pioneering company dedicated to advancing genomic research for the betterment of human health. By leveraging cutting-edge technology and an extensive database of primate genetic data, the company develops innovative tools that empower researchers to uncover new genetic targets and develop cures for rare and complex diseases.
For more information about CodeXome and Cornerstone Genomics, please visit www.cornerstonegenomics.com
“Our work has been making an impact, and we’re proud to have our story featured by Frederick Innovative Technology Center, Inc and picked up by Yahoo Finance!
With the launch of CodeXome, we’re providing researchers with new tools to explore gene function and evolution across species—advancing both human health and conservation efforts.
Take a look at what we’ve been working on and learn more about how CodeXome is shaping the future of genetic research.” – Jill Pecon-Slattery, Founder & CEO
